Medication info
Glucodown Tablet 500mg (Metformin Hydrochloride)

Glucodown Tablet 500mg (Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Hanol Bio Pharma Co., Ltd.
Appearance
White round film-coated tablet
Packaging
500 tablets/bottle
Approval status
Active

MFDS item code 200400361 · Notified 2004.06.22 · Insurance code 655602910

Summary

Main use
Treatment of type 2 diabetes mellitus
Who takes it
Adults · Children
Adult dose
The dose should be determined individually based on therapeutic response and tolerability and should not exceed the recommended maximum daily dose. To reduce gastrointestinal adverse reactions and determine the minimum dose required for adequate glycemic control, treatment with this medicine must be initiated at a low dose. Administer 500 mg 2–3 times daily with meals. Increase the dose gradually by 500 mg each week. When the dose is up to 2000 mg, it is usually divided into 2 doses daily, in the morning and evening. For doses exceeding 2000 mg, divide the dose into 3 administrations daily with meals; the maximum daily dose is 2550 mg. During initiation of therapy and dose adjustment, measure fasting blood glucose to assess response to treatment and determine the minimum effective dose. Measure blood glycated hemoglobin levels approximately every 3 months. The goal of treatment with this medicine, whether used as monotherapy or in combination with a sulfonylurea or insulin, is to reduce fasting blood glucose and blood glycated hemoglobin levels to normal or near-normal levels using the minimum effective dose. In general, when blood glucose is temporarily uncontrolled in patients whose blood glucose was controlled by diet alone, short-term administration of this medicine may be sufficient to achieve an adequate effect. This medicine may be used in patients with moderate stage 3a renal impairment (creatinine clearance [CrCl] 45≤~<60ml/min or glomerular filtration rate (GFR) 45≤~<60mL/min/1.73㎡) who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment. - The starting dose is 500mg or 850mg once daily. The maximum daily dose is 1000mg, given in 2 divided doses. Renal function should be closely monitored every 3-6 months. If creatinine clearance or glomerular filtration rate decreases to below 45ml/min or 45ml/min/1.73㎡, respectively, discontinue this medicine immediately.
Child dose
Children aged 10 years or older or adolescents who are still growing: The usual starting dose is 500 milligrams once daily, administered during or after a meal. Measure blood glucose after 1 week and adjust the dose. Gastrointestinal adverse effects may improve with gradual dose increases. The maximum daily dose is 2000mg, given in 2–3 divided doses.

Ingredients

Manufacturer
Hanol Bio Pharma Co., Ltd.

Efficacy & effects

Treatment of type 2 diabetes mellitus

  • Type 2 diabetes
  • overweight diabetes patients
View approved original text

This medication is used for patients with Type 2 diabetes who have difficulty controlling blood sugar levels with diet and exercise alone. It is particularly effective for overweight adult patients and can be used alone or in combination with other oral hypoglycemic agents or insulin. It can also be used in children aged 10 and older and adolescents in growth either as monotherapy or in combination with insulin, making it suitable for various age groups. This medication is used to improve blood sugar control to aid in the management of diabetes.

How to take

Adult dose

The dose should be determined individually based on therapeutic response and tolerability and should not exceed the recommended maximum daily dose. To reduce gastrointestinal adverse reactions and determine the minimum dose required for adequate glycemic control, treatment with this medicine must be initiated at a low dose. Administer 500 mg 2–3 times daily with meals. Increase the dose gradually by 500 mg each week. When the dose is up to 2000 mg, it is usually divided into 2 doses daily, in the morning and evening. For doses exceeding 2000 mg, divide the dose into 3 administrations daily with meals; the maximum daily dose is 2550 mg. During initiation of therapy and dose adjustment, measure fasting blood glucose to assess response to treatment and determine the minimum effective dose. Measure blood glycated hemoglobin levels approximately every 3 months. The goal of treatment with this medicine, whether used as monotherapy or in combination with a sulfonylurea or insulin, is to reduce fasting blood glucose and blood glycated hemoglobin levels to normal or near-normal levels using the minimum effective dose. In general, when blood glucose is temporarily uncontrolled in patients whose blood glucose was controlled by diet alone, short-term administration of this medicine may be sufficient to achieve an adequate effect. This medicine may be used in patients with moderate stage 3a renal impairment (creatinine clearance [CrCl] 45≤~<60ml/min or glomerular filtration rate (GFR) 45≤~<60mL/min/1.73㎡) who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment. - The starting dose is 500mg or 850mg once daily. The maximum daily dose is 1000mg, given in 2 divided doses. Renal function should be closely monitored every 3-6 months. If creatinine clearance or glomerular filtration rate decreases to below 45ml/min or 45ml/min/1.73㎡, respectively, discontinue this medicine immediately.

Child dose

Children aged 10 years or older or adolescents who are still growing: The usual starting dose is 500 milligrams once daily, administered during or after a meal. Measure blood glucose after 1 week and adjust the dose. Gastrointestinal adverse effects may improve with gradual dose increases. The maximum daily dose is 2000mg, given in 2–3 divided doses.

Precautions

This medication can cause severe lactic acidosis or hypoglycemia, requiring caution. It should not be administered to patients with moderately impaired kidney function or in acute conditions affecting kidney function such as dehydration, severe infections, or acute myocardial infarction. Patients with acute or unstable heart failure should also not use this medication. The medication must be discontinued before examinations using iodine contrast and can only be resumed after confirming normal kidney function post-examination. It is not suitable for patients with hypersensitivity to this drug or biguanides, Type 1 diabetes patients, or those with metabolic acidosis. Patients with severe infections or severe traumatic systemic disorders should temporarily stop this medication, and it should be discontinued 48 hours prior to surgery and only resumed after returning to normal kidney function. Caution is also required for patients with liver dysfunction, pulmonary embolism, severe lung impairment, and excessive alcohol consumption. This medication can frequently cause gastrointestinal side effects, and to reduce these side effects, it is advisable to take it with meals at the beginning of treatment or gradually increase the dosage. Lactic acidosis is a very rare but serious side effect, and if symptoms appear, the medication should be stopped immediately, and medical consultation should be sought. Kidney function should be regularly monitored before and during treatment, and if kidney function deteriorates, the medication should be discontinued. The risk of hypoglycemia may increase when this medication is combined with other hypoglycemic agents, so careful monitoring of blood sugar levels is necessary. Alcohol consumption can increase the risk of lactic acidosis, so excessive drinking should be avoided. Its use during pregnancy should be based on a doctor's judgment, along with necessary monitoring of fetal growth. The use of this medication while breastfeeding is not recommended, and careful consideration should be given to whether to continue breastfeeding or discontinue medication. Elderly patients are at higher risk of decreased kidney function, making dose adjustment and regular kidney function monitoring important. In the case of an overdose, blood dialysis can be used to remove the medication, and immediate medical attention is required. During treatment with this medication, regular checks of blood sugar, kidney function, and hematological values are recommended, and vitamin B12 deficiency should also be evaluated. Additionally, patients and caregivers should be thoroughly informed about the risks and symptoms of lactic acidosis and hypoglycemia, and instructed to seek immediate medical consultation upon symptom onset.

Side effects

  • Lactic acidosis
  • diarrhea
  • nausea
  • vomiting
  • abdominal distension
  • loss of appetite
  • indigestion
  • constipation
  • abdominal pain
  • metallic taste
Show 7 more
  • rash
  • anemia
  • leukopenia
  • thrombocytopenia
  • vitamin B12 deficiency
  • abnormal liver function
  • hypoglycemia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. Furthermore, it is best kept at room temperature between 1 degree and 30 degrees. Proper storage can help maintain the effectiveness of the medication for a long time.

Appearance and packaging

Appearance

White round film-coated tablet

Package unit

500 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.